From: SANTE DIRECTOR C
Sent: jeudi 27 mai 2021 14:40
To: [redacted]@incisivehealth.com'
Cc: SANTE DIRECTOR C; '[redacted]@incisivehealth.com'; [redacted]@epstra.eu'
Subject: RE: COVID-19 therapeutics strategy - request for further information

Dear [redacted],

I acknowledge receipt of your e-mail to Mr Ryan.
A reply is being prepared and will be sent to you shortly.

Kind regards,

[redacted]

[redacted]

European Commission
Directorate-General for Health and Food Safety
Directorate C – Public health

HTC [redacted]
L-2920 Luxembourg
+352 [redacted]
[redacted]@ec.europa.eu

From: [redacted] < [redacted]@incisivehealth.com>
Sent: Thursday, May 27, 2021 2:06 PM
To: RYAN John-F (SANTE) [redacted]@ec.europa.eu>
Cc: [redacted] < [redacted]@incisivehealth.com>; [redacted]
[redacted]@epstra.eu>
Subject: COVID-19 therapeutics strategy - request for further information

Dear Mr Ryan

We are contacting you on behalf of AlloVir, a clinical stage biopharmaceutical company developing novel Virus Specific T-cell therapies to treat or prevent life-threatening viral infections in high-risk patients. We are reaching out to you in the context of the Commission's recent COVID-19 therapeutics strategy announcement. AlloVir has a T-cell therapy for the

treatment of High-Risk Patients with COVID-19 that received FDA clearance to start clinical trials in September 2020.

We have understood from your intervention in the European Parliament's ENVI Committee on 26 May, that the Commission will be reviewing candidate therapeutics and shortlisting ten by the end of June. AlloVir would be interested in understanding what the formal process to enter this is and how AlloVir should approach the Commission and the EMA.

We look forward to your response and please feel free to contact us should you have any questions.

Best wishes

[redacted]

[redacted]

M +32 [redacted]
E [redacted]@incisivehealth.com
www.incisivehealth.com

Incisive Health
An Ashfield Health Company

make it matter.

Part of UDG Healthcare plc

Incisive Health, Avenue Louise 54, 1050 Brussels